EPIS-B Episurf Medical AB (publ)
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient's distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. It also holds logistics and warehouse properties in Helsinki and Kerava. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Episurf Medical (STO: EPIS-B)
›
Episurf Medical (STO: EPIS-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 22 employees.
The shares were at 0.0554 SEK on 20 November 2026, up 69.2% over 52 weeks. Its 52-week range is 0.0245 SEK to 0.2900 SEK: the price is 80.9% below the high and 126.1% above the low.
Its market capitalisation is 840.08M SEK.
Episurf Medical reports return on equity of -122.5%, an operating margin of -185.1% and revenue up 412.5% year over year.
Its debt exceeds its cash by 262.70M SEK, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.